Clinical and Imaging Outcomes of the Upside‑Down Pars Plana Ahmed Glaucoma Valve Implantation: A Follow‑Up to Our Initial Report

倒置式睫状体扁平部艾哈迈德青光眼引流阀植入术的临床和影像学结果:我们初步报告的后续研究

阅读:1

Abstract

INTRODUCTION:  Tube shunts are essential for refractory glaucoma, yet plate encapsulation can compromise long-term efficacy. We evaluated long-term clinical and imaging outcomes of an "upside-down" Ahmed glaucoma valve (AGV) technique via the pars plana, which may favorably modify bleb architecture. METHODS:  This retrospective observational study included 10 eyes from 10 patients who underwent pars plana AGV implantation with the valve plate flipped upside down to direct the drainage port toward the scleral surface. Outcomes included intraocular pressure (IOP), glaucoma medication score, postoperative complications, and corneal endothelial cell density (ECD). Orbital magnetic resonance imaging (MRI) was performed in two eyes to assess bleb morphology. RESULTS:  Mean follow-up was 45.9 ± 24.2 months. Mean preoperative IOP decreased from 35.8 ± 4.4 to 14.9 ± 0.6 mmHg at 66 months (p < 0.05). The glaucoma medication score decreased from 4.6 ± 0.7 to 2.4 ± 0.5 at 42 months (p < 0.05). Transient postoperative hypertension occurred in seven eyes and resolved without surgical intervention. Three patients lost light perception due to retinal ischemia related to the underlying disease. No persistent hypotony or tube exposure was observed. Orbital MRI obtained at approximately six years postoperatively demonstrated preservation of a double-layered peri-endplate bleb configuration in two eyes. The average monthly ECD loss rate was 0.28% ± 0.26%. CONCLUSIONS:  The upside-down pars plana AGV technique achieved sustained IOP reduction through 66 months and suggested stable long-term bleb morphology on MRI without adjunctive antifibrotic agents. This approach may be a useful option for complex refractory glaucoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。